News | October 27, 2025
Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Subscribe To Our Newsletter & Stay Updated
